NCT07588165 Pain Assessment During Rapid Sequence Induction
| NCT ID | NCT07588165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Princesse Grace |
| Condition | Rapide Sequence Induction |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-05-21 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-05-21 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rapid sequence induction (RSI) is a standard anesthesia technique used in patients at risk of aspiration. Although tracheal intubation following RSI is a frequent and painful procedure, no study has yet evaluated nociception using the Analgesia Nociception Index (ANI) during this procedure. This monocentric prospective observational study aims to describe the impact of RSI on pain measured by ANI, and to explore early complications (desaturation, hypotension, regurgitation) and factors associated with pain and complications. 150 patients undergoing RSI in the visceral surgery operating room at CHPG Monaco will be analyzed.
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years * Patient requiring tracheal intubation after rapid sequence induction in the visceral surgery operating room * Pain monitoring by Analgesia Nociception Index (ANI) as part of general anesthesia Exclusion Criteria: * Patient with atrial fibrillation at the time of intubation following rapid sequence induction * Patient on long-term beta-blocker therapy
Contact & Investigator
Remy WIDEHEM, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Princesse Grace
Frequently Asked Questions
Who can join the NCT07588165 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rapide Sequence Induction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07588165 currently recruiting?
Yes, NCT07588165 is actively recruiting participants. Contact the research team at remy.widehem@chpg.mc for enrollment information.
Where is the NCT07588165 trial being conducted?
This trial is being conducted at Monaco, Monaco.
Who is sponsoring the NCT07588165 clinical trial?
NCT07588165 is sponsored by Centre Hospitalier Princesse Grace. The principal investigator is Remy WIDEHEM, MD at Centre Hospitalier Princesse Grace. The trial plans to enroll 150 participants.